NovoCure Analyst Price Targets - Benzinga

NovoCure Ltd

NVCRNASDAQ

Trade with Public

Trade with Public

$17.94

0.301.7%

At close: Sep 4, 5:00 PM EST

$17.94

N/A

After Hours: Sep 4, 4:00 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

NovoCure Analyst Price Targets

Wall Street analyst price targets and consensus rating for NovoCure (NVCR).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$27Upside to Avg. PT+51.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 24, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$18→$20
Jul 23, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$46→$52
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$17
Jun 18, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$48→$46
May 4, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$14→$17
May 1, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$16→$20
Apr 16, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$18
Feb 26, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$47→$49
Feb 12, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$39→$47
Jan 15, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$18
Jan 13, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$42→$39
Oct 30, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$38→$42
Oct 27, 2025	JP Morgan	Jessica Fye	PT Cut	Neutral	$25→$23
Jul 25, 2025	Wells Fargo	Larry Biegelsen	Downgrade	Overweight→Equal-Weight	$40→$15
Jul 8, 2025	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$30
Jun 27, 2025	Piper Sandler	Jason Bednar	Maintained	Overweight	$34
Apr 23, 2025	Piper Sandler	Jason Bednar	PT Cut	Overweight	$42→$34
Apr 16, 2025	Wedbush	David Nierengarten	PT Cut	Neutral	$29→$27
Apr 10, 2025	JP Morgan	Jessica Fye	PT Cut	Neutral	$29→$28
Jan 14, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$38

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20

Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $46 to $52.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Neutral on NovoCure, Announces $17 Price Target

JP Morgan analyst Jessica Fye reinstates NovoCure (NASDAQ:NVCR) with a Neutral and announces $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NovoCure, Lowers Price Target to $46

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Buy and lowers the price target from $48 to $46.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on NovoCure, Raises Price Target to $17

Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and raises the price target from $13.5 to $17.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on NovoCure, Raises Price Target to $20

Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and raises the price target from $16 to $20.

Benzinga Newsdesk